Klaus Schmierer

Portugal

Research Interests

Explore related searches

Professors in Portugal Professors in Immunology Immunology professors in Portugal

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (11)

David Thomas

Associate Professor

UCL Institute of Neurology, University College London

UNITED KINGDOM

View details

Suzanne Hodgkinson

Assoc Professor

UNSW Sydney

AUSTRALIA

View details

Laura Smith

Lecturer in Health Psychology

Queen Mary University of London

UNITED KINGDOM

View details

Manuel Salavisa

Lecturer

Universidade Católica Portuguesa

PORTUGAL

View details

Letizia Leocani

Vita-Salute San Raffaele University

ITALY

View details

Angray Kang

Professor in Immunotechnology

Queen Mary University of London

UNITED KINGDOM

View details

Marc Miquel

Head of Magnetic Resonance and Non-Ionising Radiation Physics

Guy's and St Thomas' NHS Foundation Trust

UNITED KINGDOM

View details

Tobias Wood

King’s College London

UNITED KINGDOM

View details

Emma Tallantyre

Clinical Reader

Cardiff University

UNITED KINGDOM

View details

nikos evangelou

Clinical Associate Professor of Neurology

University of Nottingham

UNITED KINGDOM

View details

Avril Drummond

Visiting professor in occupational therapy

University of Ulster

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Klaus Schmierer

Research Interests

Explore related searches

Contact this professor

Articles (17)

Mechanistic biology linking traumatic brain injury to multiple sclerosis susceptibility

Neurofilament heavy chain in secondary progressive multiple sclerosis

Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study

The shoulders we keep standing on: remembering Otto Marburg, a big brain in neurology and multiple sclerosis, at 150

Parakinesia Brachialis Oscitans in a Patient With a First Manifestation of Multiple Sclerosis

Honing in on magnetic resonance imaging predictors of multiple sclerosis pathology

A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets

Parakinesia Brachialis Oscitans in a Patient With a First Manifestation of Multiple Sclerosis

Organic solvents and Multiple Sclerosis: the doubled risk dilemma

High‐resolution quantitative MRI of multiple sclerosis spinal cord lesions

Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): protocol for a mixed-methods, multicentre feasibility randomised controlled trial

Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis

Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis

Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?

MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Commentary

Challenges in multiple sclerosis care: Results from an international mixed-methods study

Highly effective disease-modifying treatment as initial MS therapy.

Collaborators (11)

David Thomas

Suzanne Hodgkinson

Laura Smith

Manuel Salavisa

Letizia Leocani

Angray Kang

Marc Miquel

Tobias Wood

Emma Tallantyre

nikos evangelou

Avril Drummond

Make your next move.